News articles about Simulations Plus (NASDAQ:SLP) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Simulations Plus earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news coverage about the technology company an impact score of 46.5630281275458 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Simulations Plus (NASDAQ SLP) traded down 2.41% during midday trading on Friday, hitting $14.20. 42,803 shares of the stock were exchanged. Simulations Plus has a 12-month low of $7.90 and a 12-month high of $16.15. The firm has a 50 day moving average of $14.17 and a 200 day moving average of $11.94. The firm has a market cap of $244.88 million, a P/E ratio of 45.08 and a beta of -0.71.
Simulations Plus (NASDAQ:SLP) last announced its earnings results on Friday, July 14th. The technology company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The business had revenue of $6.75 million during the quarter, compared to the consensus estimate of $6.48 million. Simulations Plus had a net margin of 24.86% and a return on equity of 23.21%. Equities analysts forecast that Simulations Plus will post $0.32 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Friday, July 28th were issued a $0.05 dividend. The ex-dividend date of this dividend was Wednesday, July 26th. This represents a $0.20 annualized dividend and a yield of 1.41%. Simulations Plus’s dividend payout ratio is presently 62.50%.
SLP has been the subject of several recent research reports. Zacks Investment Research cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Thursday, April 27th. BidaskClub lowered shares of Simulations Plus from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Simulations Plus (NASDAQ:SLP) Share Price” was first published by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/simulations-plus-nasdaqslp-receives-daily-news-sentiment-score-of-0-19-updated.html.
In related news, President Thaddeus Henry Grasela, Jr. sold 5,812 shares of the company’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $11.65, for a total value of $67,709.80. Following the sale, the president now directly owns 426,852 shares of the company’s stock, valued at $4,972,825.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Walter S. Woltosz sold 18,500 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $15.07, for a total transaction of $278,795.00. Following the completion of the sale, the chief executive officer now directly owns 5,684,916 shares in the company, valued at $85,671,684.12. The disclosure for this sale can be found here. Insiders sold 93,743 shares of company stock worth $1,154,108 over the last ninety days. 36.93% of the stock is currently owned by corporate insiders.
Simulations Plus Company Profile
Simulations Plus, Inc (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour.
Receive News & Ratings for Simulations Plus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.